albuterol


Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to albuterol: Albuterol sulfate

al·bu·ter·ol

 (ăl-byo͞o′tə-rôl′)
n.
A beta-adrenergic drug, C13H21NO3, used in the form of its sulfate as a bronchodilator primarily to treat asthma and chronic obstructive pulmonary disease. Also called salbutamol.

[al(pha) + blend of but(yl) and -terol (ultimately shortening of (ar)terenol, norepinephrine hydrochloride, originally a trademark).]

albuterol

(ælˈbjuːtəˌrɒl)
n
a bronchodilator used by sufferers of asthma, emphysema, and other lung conditions, to treat symptoms such as wheezing or shortness of breath
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.albuterol - a bronchodilator (trade names Ventolin or Proventil) used for asthma and emphysema and other lung conditionsalbuterol - a bronchodilator (trade names Ventolin or Proventil) used for asthma and emphysema and other lung conditions; available in oral or inhalant forms; side effects are tachycardia and shakiness
bronchodilator - a drug that relaxes and dilates the bronchial passageways and improves the passages of air into the lungs
Translations

albuterol

n salbutamol m, albuterol m
References in periodicals archive ?
Data are limited on the impact of cost-sharing on acute medications such as rescue medications for asthma like albuterol, for which patients or parents may have different price elasticities (i.
After excluding the patients who needed emergent and negative bronchoscopies, the remaining clinically stable 84 patients were compared for the effects of preoperative administration of nebulized albuterol and budesonide combination on bronchoscopy complications.
With the side chain (tail) anchored in the exosite, the active saligenin head binds to and activates the [beta] receptor at the same location as albuterol.
A 2014 study established that continuous albuterol can be initiated safely in the nonintensive pediatric care setting, but not all hospitals have followed suit (Pediatrics 2014;134[4]:e976-82).
Israel-based Teva Pharmaceuticals' new drug application for albuterol multi-dose dry-powder inhaler, an investigational breath-actuated dry-powder inhaler to treat or prevent bronchospasm in patients 12 years of age and older with reversible obstructive airway disease, has been accepted for review by the US Food and Drug Administration, it was reported yesterday.
With respect to previously published studies, an increased risk for congenital anomalies in general or orofacial clefts in particular, has not been suggested for albuterol.
The product, marketed as Combivent Respimat inhalation spray, does not contain chlorofluorocarbons (CFCs) and "is a suitable alternative for patients who are currently using Combivent (ipratropium bromide and albuterol sulfate) inhalation aerosol," according to the statement, issued by the Division of Drug Information (DDI) in the FDA's Center for Drugs, Evaluation and Research (CDER).
Albuterol relaxes the smooth muscle cells in the bronchioles, dilating the air passages to the lungs and making breathing easier.
Half of those who used the albuterol reported feeling better.
Those who got albuterol reported a 50 per cent improvement in symptoms.
Albuterol sulfate-commonly used to treat bronchospasm, a constriction of the airways within the lungs as often occurs in asthma-may decrease interleukin-12 levels, the authors note.
The observation that a high fat meal changes the asthmatic response to albuterol was unexpected as we hadn't considered the possibility that this would occur.